E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic Obstructive Pulmonary Disease (COPD) |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10010952 |
E.1.2 | Term | COPD |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to estimate the bronchodilator effect of QMF Twisthaler® 250/400 µg q.d. vs. fluticasone propionate/salmeterol MDDPI 250/50 µg b.i.d. over 24 hours in subjects with moderate to severe COPD across a range of endpoints and to select clinically meaningful endpoints for potential use in a pivotal registration phase III study. |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
•Male and female adult patients aged > 40 years, who have signed an Informed Consent Form prior to initiation of any study-related procedure, including any adjustments to COPD medication prior to Visit 1. •Patients with a diagnosis of moderate to severe COPD as classified by the GOLD guidelines (2006) and who additionally meet the following criteria: a) Ex-smoker or current smoker with a smoking history of at least 10 pack years. NOTE: Current smokers must provide verbal notification or written documentation that attests to their inability to stop smoking after participation (or declining to participate) in a smoking cessation program. Ex-smokers are defined as those who have stopped smoking at least 12 months prior to Visit 1. b) Post-bronchodilator FEV1 at Visit 1 between 30 and 65% of the predicted normal value [Quanjer et al. 1994]. This criterion for FEV1 will have to be demonstrated after a washout period of at least 6 hr during which no short acting 2-agonist has been inhaled, 8 hr for short acting anti-cholinergic, or FDC of inhaled anticholinergic/SABA, and 48 hr for ICS, long-acting β2-agonists or FDC of ICS/β2 agonist c) Post-bronchodilator FEV1/FVC < 70% d) TLC or FRC of 120% of the predicted normal value for those patients undergoing the body plethysmography assessments. (Post-bronchodilator refers to measurements approximately 30 minutes after inhalation of 4 inhalations of 100/90 µg of salbutamol/albuterol MDI or equivalent dose of DPI) •Patients must be on only short acting β2 agonist for relief for at least 7 days prior to randomization (Visit 2)
|
|
E.4 | Principal exclusion criteria |
•Pregnant women, nursing mothers, or females of childbearing potential, regardless of whether or not sexually active, if they are not using a reliable form of contraception. •Patients with COPD exacerbation within 4 weeks prior to randomization which requires medical intervention or treatment with additional excluded medication. •Patients demonstrating an increase in FEV1 ≥ 400 mL 30 minutes after administration of four inhalations of 100/90 µg salbutamol/albuterol at the screening visit. •Patients requiring oxygen therapy (>15 hr a day) for chronic hypoxemia (`prn’ use up to 10 hr total in any given 24 hr period is acceptable). •Patient with an acute respiratory tract infection within 4 weeks prior to Visit 1. Patients who develop a respiratory tract infection between Visit 1 and visit 2 must discontinue from the trial, but may be permitted to re-screen at a later date (at least 4 weeks after the resolution of the respiratory tract infection).
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
This is a pilot study, no primary statistical hypothesis is assumed and no power calculation will be generated for the sample size. The treatment comparison will be made for QMF Twisthaler® and fluticasone propionate/salmeterol MDDPI on a range of endpoints; •FEV1 and FVC at -20 minutes prior to dosing •FEV1 and FVC at 5 and 30 minutes, 1, 2, 3, 4 hrs post dosing (Days 1, 27, 54) and 10, 11, 12hrs 15min, 14, 16, 18, 20, 22, 23 hrs 45 min. post dosing (Days 2, 28, 55 ) •Peak FEV1 (FVC) and time to peak FEV1 (FVC) •Onset of action (time at which there is a 12% improvement in mean FEV1 from baseline) •Duration of action (duration at which there is a 12% improvement in mean FEV1 from baseline) •FEV1 (FVC) standardized area under the curve from 0-24 hours •Inspiratory Capacity (IC) and Functional Residual Capacity (FRC) measured by body plethysmography at 40 minutes prior to dosing (Days 1, 27, 54) and 11hrs 40 min and 23hrs 40 minutes after dosing (Days 2, 28, 55 ). •Daily Pre dose FEV1 (FVC) (AM and PM pre dose) by portable spirometer/e-Diary device between the study visits. •Daytime and night time COPD symptoms including: wheezing, cough and difficulty breathing •Use of rescue medication
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Information not present in EudraCT |
E.8.4 | The trial involves multiple sites in the Member State concerned | Information not present in EudraCT |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 12 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | 70 |
E.8.9.2 | In all countries concerned by the trial days | 70 |